Drug Search Results
More Filters [+]

Teriflunomide

Alternative Names: teriflunomide, aubagio, hmr1726
Latest Update: 2024-11-21
Latest Update Note: Clinical Trial Update

Product Description

Teriflunomide is in a class of medications called immunomodulatory agents. It is thought to work by decreasing inflammation and decreasing the action of immune cells that may cause nerve damage. (Sourced from: https://medlineplus.gov/druginfo/meds/a613010.html)

Mechanisms of Action: DHODH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Known Adverse Events: Headache | Alopecia | Diarrhea

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Teriflunomide

Countries in Clinic: Argentina, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Multiple Sclerosis

Phase 1: Multiple Sclerosis, Relapsing-Remitting

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2018-001292-21

P3

Active, not recruiting

Multiple Sclerosis

2025-07-04

GEMINI 2

P3

Completed

Multiple Sclerosis

2024-07-16

GEMINI 1

P3

Completed

Multiple Sclerosis

2024-07-15

CTR20222095

P1

Recruiting

Multiple Sclerosis, Relapsing-Remitting

None

Recent News Events